glp 1 r peptide GLP-1 Receptor Agonist Services for Type 2 Diabetes and Obesity Drug Development The Glucagon-Like Peptide-1 Receptor (GLP-1R)

Will 10 million people die a year due to antimicrobial resistance by 2050

Oeschlagel U, Nowak R, Zengler H, Hoffmann R, Naumann R, Ehninger G, Andreeff M

Phenytoin-potentiated hepatotoxicity following acetaminophen overdose

Furthermore, while the efficacy of these synthetic drugs is remarkably high, the burden of gastrointestinal adverse events remains a challenge that requires carefully monitored dose escalation

It calls for coordinated research, regulatory action, professional engagement and equitable, timely adoption of effective therapies

These significant results have prompted further in-depth research on tirzepatide, such as the SURMOUNT initiative, to evaluate its potential as a therapeutic agent for obesity